Open AccessRANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
Author(s) -
Hong Wang,
Reading Ashton,
Jonathan A. Hensel,
Joo Hyoung Lee,
Vinayak Khattar,
Yong Wang,
Jessy Deshane,
Selvarangan Ponnazhagan
Publication year - 2020
Publication title -
molecular cancer therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.717
H-Index - 173
eISSN - 1538-8514
pISSN - 1535-7163
DOI - 10.1158/1535-7163.mct-20-0378
Subject(s) - osteoprotegerin , rankl , osteoclast , medicine , cancer research , breast cancer , denosumab , immunosuppression , immunology , bone remodeling , cancer , receptor , activator (genetics) , osteoporosis
Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role of receptor activator of NF-κB ligand (RANKL) beyond skeletal pathology in breast cancer, including tumor growth and immunosuppression. By using an osteoprotegerin (OPG) variant, which we developed recently through protein engineering to uncouple TNF-related apoptosis-inducing ligand (TRAIL) binding, this study established the potential of a cell-based OPG Y49R therapy for both bone damage and immunosuppression in an immunocompetent mouse model of orthotopic and metastatic breast cancers. In combination with agonistic death receptor (DR5) activation, the OPG Y49R therapy significantly increased both bone remolding and long-term antitumor immunity, protecting mice from breast cancer relapse and osteolytic pathology. With limitations, cost, and toxicity issues associated with the use of denosumab, bisphosphonates, and chemotherapy for bone metastatic disease, use of OPG Y49R combination could offer a viable alternate therapeutic approach.